EFPIA, the voice of the pharmaceutical research in Europe, has published the results of their verification of the pilot product. The pilot, which was held in Sweden between September 2009 and January 2010, was able to prove that a system of product verification at the point of distribution, based on a two-dimensional data matrix is both robust and efficient.The next generation Edwards SAPIEN XT valve PARTNERS II study was designed to provide a better model of the gate on the cardiac valve surgery, and potentially reduce complications of treatment.
The project also had the support of pharmaceutical distributors Tamro and KD Pharma and the collaboration of LIF, the Swedish Pharmaceutical Manufacturers Association. ‘Packs of 14 producers were provided with 2-D arrays of data, allowing each packet to be identified individually. The solution could provide a valuable EFPIA in reducing the risk of counterfeit medicines reaching patients through the legitimate supply chain.
The main results of the project, note that the system provides effective detection of counterfeit and expired packages of packages, or short-term and recalled products. There was a clear need for packaging to have only a single bar code, users were sometimes confused by the presence of more than one code on the package.
The results clearly indicate that the proposed model is feasible EFPIA, proportionate, secure and convenient.